AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

NGNE · NASDAQ · Biotechnology

Neurogene (NGNE)

Builds a single gene therapy for Rett syndrome using a proprietary expression-control platform.

$33.60

After hours+0.02 (+0.06%)

At close$33.58(+3.10%)

Bank of New York Mellon Corp Purchases New Position in Neurogene Inc. $NGNE
Defense WorldSep 11Ownership
BlackRock Inc. Invests $33.27 Million in Neurogene Inc. $NGNE
Defense WorldSep 2Ownership
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
GuruFocusAug 11
Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
Business WireAug 11
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business WireJul 6
Neurogene Inc. Announces Pricing of $125 Million Public Offering
Business WireJul 1
Neurogene Inc. Announces Proposed Public Offering
Business WireJun 30
Neurogene Inc. (NGNE) Discusses Updated Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome Transcript
Seeking AlphaJun 29
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
GuruFocusJun 29
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
Business WireJun 29
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
GuruFocusJun 8
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
Business WireJun 8
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business WireJun 2
Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates
Business WireMay 12
Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy
Business WireMay 12
Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy
Business WireApr 28
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
Business WireApr 20
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business WireApr 8
Brokerages Set Neurogene Inc. (NASDAQ:NGNE) Price Target at $44.00
Defense WorldApr 7
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
Business WireMar 24